New bladder cancer drug aims to match gold standard in major trial

NCT ID NCT05037279

First seen Apr 12, 2026 · Last updated May 14, 2026 · Updated 4 times

Summary

This Phase 3 trial tests a new treatment called VERITY-BCG for people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG therapy before. The study compares VERITY-BCG to the standard BCG treatment (OncoTICE) to see if it works just as well at preventing cancer from coming back within 2 years. About 540 adults will take part, and the goal is to offer a safe, effective alternative for managing this type of bladder cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Site 01

    RECRUITING

    Toronto, Ontario, Canada

    Contact

  • Site 02

    NOT_YET_RECRUITING

    Toronto, Ontario, Canada

    Contact

  • Site 04

    RECRUITING

    Kingston, Ontario, Canada

    Contact

  • Site 05

    RECRUITING

    Vancouver, British Columbia, Canada

    Contact

  • Site 08

    RECRUITING

    Toronto, Ontario, Canada

  • Site 10

    NOT_YET_RECRUITING

    Montreal, Quebec, Canada

    Contact

Conditions

Explore the condition pages connected to this study.